1 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Clinical Exposure Evaluation Hans J. Roethig, MD, PhD, FCP, FFPM.

Slides:



Advertisements
Similar presentations
Estimating the detector coverage in a negative selection algorithm Zhou Ji St. Jude Childrens Research Hospital Dipankar Dasgupta The University of Memphis.
Advertisements

Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
PHARMACOKINETIC.
ASSESSING RESPONSIVENESS OF HEALTH MEASUREMENTS. Link validity & reliability testing to purpose of the measure Some examples: In a diagnostic instrument,
Non compartmental analysis
Exposure Assessment Thanks to Marc Rigas, PhD for an earlier version of this lecture Much of the materials is drawn from Paustenbach, DJ. (2000) The practice.
Copyright 2002 Marc Rigas Issues in Exposure Assessment Marc L. Rigas, Ph.D. National Exposure Research Laboratory, U.S. Environmental Protection Agency.
Selected bioavailability and pharmacokinetic calculations Dr. Osama A. A. Ahmed.
Pharmacokinetics & Pharmacodynamics of Controlled Release Systems Presented By: Govardhan.P Dept. of pharmaceutics, University College of Pharmaceutical.
One-compartment open model: Intravenous bolus administration
Cotinine is an Unreliable Biomarker for Systemic Exposure in Spit Tobacco Users Jon O. Ebbert, MD, MSc Lowell C. Dale, MD Liza Nirelli Darrell Schroeder,
Practical Pharmacokinetics
THE PHYSIOLOGY OF FITNESS
Purpose The National Physical Activity Guidelines Dimensions of Physical Activity Methods used to Measure Physical Activity Appropriate instruments for.
Supercourse Environmental Exposure Assessment And Biomarkers Wael Al-Delaimy, MD, PhD.
BIOLOGIC MARKERS IN OCCUPATIONAL AND ENVIRONMENTAL MEDICINE By: Dr Chavoshi.
Pharmacokinetics (PK): What the body does to the drug? Most drugs: Enter the body by crossing barriers Distributed by the blood to the site of action Biotransform.
Committee on Carcinogenicity (COC) Approach to Risk Assessment of Genotoxic Carcinogens David H. Phillips* COC Chairman Descriptive vs. Quantitative.
Gokaraju Rangaraju College of Pharmacy
Psychology of Learning EXP4404 Chapter 2: The Study of Learning and Behavior Dr. Steve.
Introduction to Pharmacology PHARM TECH. Pharmacology  Pharmacology is the science that deals with the study of therapeutic (beneficial) agents.  Knowledge.
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
Copyright © 2002 University of Maryland School of Nursing. All rights reserved. Comparison of Pharmacology and Toxicology This material was developed at.
Animal Studies and Human Health Consequences Sorell L. Schwartz, Ph.D. Department of Pharmacology Georgetown University Medical Center.
Nicotine Dependence: Comparing Menthol and Non-Menthol Cigarette Smokers Qiang Li, MS Andrew Hyland, PhD Gary Giovino, MS, PhD Joseph Bauer, PhD Michael.
Preliminary Thoughts on Evaluating Harm Reduction Claims Based on the Mass SAB Experience 2003 National Conference on Tobacco or Health David Burns MD.
3. Method of inspection Requirements for the Method of Inspection We assume that k a is much larger than k el. That is, k a is at least five times greater.
1 ORALLY INHALED AND NASAL DRUG PRODUCTS FOR LOCAL ACTION Current FDA BA/BE Background and Issues Wallace P. Adams, Ph.D. OPS/CDER/FDA OINDP Subcommittee.
PHARMACOKINETIC MODELS
Pharmacokinetics of Antimicrobials in Animals: Lessons Learned William A. Craig, M.D. University of Wisconsin-Madison.
Population Pharmacokinetic Characteristics of Levosulpiride and Terbinafine in Healthy Male Korean Volunteers Yong-Bok Lee College of Pharmacy and Institute.
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas.
The General Concepts of Pharmacokinetics and Pharmacodynamics
EHS 507 Potential dose: the amount of chemical that is ingested or inhaled, or the amount of chemical contained in material applied to skin. Applied dose:
TOXICOLOGY OCCUPATIONAL HAZARDS CHEMICAL PHYSICAL ERGONOMIC PSYCHOLOGIC BIOLOGIC.
INTRODUCTION CLINICAL PHARMACOKINETICS
BIOPHARMACEUTICS.
Introduction of Biopharmaceutics and Pharmacokinetics
1 Pharmacokinetics: Introduction Dr Mohammad Issa.
© Paradigm Publishing, Inc.1 Chapter 2 Basic Concepts of Pharmacology.
Modified release products. Considerations in the evaluation of modified release products Requirements for preparing extended release products. The bioavailability.
Design of Sustained Release Dosage Forms
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
11/6/03LSRO presentation Draft for discussion PM USA Mission Our goal is to be the most responsible, effective and respected developer, manufacturer and.
The General Concepts of Pharmacokinetics and Pharmacodynamics
415 PHT Plasma Level – Time Curve
1 Biopharmaceutics Dr Mohammad Issa Saleh. 2 Biopharmaceutics Biopharmaceutics is the science that examines this interrelationship of the physicochemical.
Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.
Basic Concepts of Pharmacology © Paradigm Publishing, Inc.
Manganese Biomonitoring for assessment of Exposure to Airborne Manganese in Foundry Plants Dr. Seyedtaghi Mirmohammadi Assistant Professor. Indoor Air.
Definitions and Concepts
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
Drug Response Relationships
Physiology for Engineers
Biologic Monitoring A. H. Mehrparvar, MD
HYGIENE STANDARDS AND OCCUPATIONAL EXPOSURE LIMITS
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Quantitative Pharmacokinetics
Biopharmaceutics Dr Mohammad Issa Saleh.
Kinetics, Modeling Oct 15, 2006 Casarett and Doull,
Food Chemicals Toxicity
Selected Bioavailability and Pharmacokinetic Calculations
Chapter 1 Introduction of Pharmacology [,fɑ:mə'kɔlədʒi] 药理学
Therapeutic Drug Monitoring chapter 1 part 1
The NIDA Standardized Research E-Cigarette (SREC)
Nanoemulsions as Versatile Formulations for Paclitaxel Delivery: Peroral and Dermal Delivery Studies in Rats  Sateesh Khandavilli, Ramesh Panchagnula 
Presentation transcript:

1 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Clinical Exposure Evaluation Hans J. Roethig, MD, PhD, FCP, FFPM Director Clinical Evaluation Philip Morris USA, Inc.

2 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Exposure Exposure Nicotine equivalents concept Nicotine equivalents concept Smoking topography Smoking topography Study design Study design Case studies Case studies

3 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Exposure Exposure Nicotine equivalents concept Nicotine equivalents concept Smoking topography Smoking topography Study design Study design Case studies Case studies

4 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only 4 Definitions of Exposure Exposure is the contact over time and space between a person and one or more biological, chemical or physical agents (US NRC, 1991) Exposure is the contact over time and space between a person and one or more biological, chemical or physical agents (US NRC, 1991) Exposure is the concentration of a substance in the human body over time, (c x t) Exposure is the concentration of a substance in the human body over time, (c x t) Exposure can be measured as the area under the concentration-time-curve, (AUC) Exposure can be measured as the area under the concentration-time-curve, (AUC)

5 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Where Can We Determine Exposure? Respiratory tract Respiratory tract Central compartment Central compartment Tissues Tissues

6 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Exposure Exposure Nicotine equivalents concept Nicotine equivalents concept Smoking topography Smoking topography Study design Study design Case studies Case studies

7 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Nicotine Equivalents = Molar Sum of Nicotine and its 5 Major Metabolites

8 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Daily Nicotine Equivalents Excretion

9 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Daily Nicotine Equivalent Excretion Per Cigarette

10 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only

11 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Exposure Exposure Nicotine equivalents concept Nicotine equivalents concept Smoking topography Smoking topography Study design Study design Case studies Case studies

12 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Clinical Research Support Systems (CReSS) Plowshares Technologies, Inc. Lab-based CReSS

13 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Topography Measurement CReSS Puffing Parameters Puff Volume Puff Volume Puff Duration Puff Duration Inter-Puff Interval Inter-Puff Interval Peak Flow Peak Flow Time of Peak Flow Time of Peak Flow Puffs per Cigarette Puffs per Cigarette Time to First Puff Time to First Puff Time to Removal Time to Removal Date and Time Date and Time

14 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Flow (ml/sec) » Threshold » Total recorded puff volume Puff volume not recorded Device detects start of puff >> Device detects end << of puff Puff Duration CReSSmicro® Threshold

15 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Source of Data Data from 3 clinical short term exposure studies and 1 long term study; n=363 subjects and n>7260 observations of puffing parameters Data from 3 clinical short term exposure studies and 1 long term study; n=363 subjects and n>7260 observations of puffing parameters

16 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only

17 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only

18 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Relationship between Exposure and Puffing Profile Total puff volume (TPV), total inter- puff interval (TPI) and number of cigarettes smoked were significantly correlated (r 2 =0.57, p<0.001) with nicotine equivalents per cigarette (NE) Total puff volume (TPV), total inter- puff interval (TPI) and number of cigarettes smoked were significantly correlated (r 2 =0.57, p<0.001) with nicotine equivalents per cigarette (NE) nicotine equivalents nicotine equivalents TPI= ∑ Inter-puff interval / Number of cigarettes

19 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Exposure Exposure Nicotine equivalents concept Nicotine equivalents concept Smoking topography Smoking topography Study design Study design Case studies Case studies

20 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only 20 Reduced Exposure Claims IOM, 2001: “.. For most such products the scientific evidence supporting exposure reduction claims will come from in-vitro studies, animal studies, and pharmacokinetic studies in humans.” (emphasis added)

21 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only CC 1 Baseline R a n d o m i z a t i o n CC 1 CC 2 EHCSS No-Smoking Clinical Study Design: Randomized Forced-Switching Forced-switching Day - 2 Day -1 Day EHCSS uncontrolled CC 1 Acclima tion

22 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Exposure Assessment Exposure Assessment Exposure = f {cigarette design/brand} f {cigarette design/brand} x f {smoking behavior} x f {smoking behavior} x number of cigarettes x f {ADME of the individual} ADME = absorption, distribution, metabolism, elimination

23 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Controlled Smoking Day –2 (before randomization): Acclimation day Acclimation day  Subjects smoking the same conventional cigarette only  Subjects allowed to smoke as many cigarettes as reported in their smoking history plus 20%  Subjects are monitored for actual cigarette consumption to determine their daily allotment for the remainder of the study (days -1 to 8). This determines the maximum daily allowance ( cigarettes per day)  Smoking allowed only at predetermined smoking times from 7 AM to 11 PM (every 32 minutes, maximally 30 smoking times)  Cigarettes to be smoked evenly over the day

24 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Daily Nicotine Equivalents Excretion

25 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Carboxyhemoglobin (AUC)

26 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Minimum Detectable Difference Between Study Groups In Biomarkers of Exposure* (% Change from Baseline) BiomarkerVariability Detectable Difference [%] Nicotine equivalents COHb *Assuming 80% power, 5 % type I error rate, two-sided test, n=20 per group

27 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Exposure Assessment Exposure Assessment Exposure = f {cigarette design/brand} x f {smoking behavior} f {cigarette design/brand} x f {smoking behavior} x number of cigarettes x f {ADME of the individual} ADME = absorption, distribution, metabolism, elimination

28 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Long Term Exposure Study Design  Continuation of Short Term Study  Unrestricted smoking, free cigarettes  Biomarkers of Exposure to be reported after 3 and 6 months

29 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Exposure Exposure Nicotine equivalents concept Nicotine equivalents concept Smoking topography Smoking topography Study design Study design Case studies Case studies

30 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Case Study 1 Comparison of 2 cigarettes: 1. Reference cigarette identified 2. Reference cigarette unidentified Same FTC tar delivery, same taste

31 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Mean + SD

32 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Mean + SD

33 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Case Study 2 Comparison of 2 cigarettes: 1. Reference cigarette 2. Test cigarette Same FTC tar delivery, different taste

34 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Mean + SD

35 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Mean + SD

36 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Mean + SD

37 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Case Study 3 Comparison of 3 cigarettes: 1. 2 Reference cigarettes 2. Test cigarette Different FTC tar delivery, different taste

38 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Smoking Topography

39 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Smoking Topography

40 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Puffing profiles are altered immediately when switching to a different cigarette type but remain constant for the rest of the study Puffing profiles are altered immediately when switching to a different cigarette type but remain constant for the rest of the studyswitching

41 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Conclusions We have validated a clinical study design for the evaluation of cigarettes concerning smoking behavior and exposure. We have validated a clinical study design for the evaluation of cigarettes concerning smoking behavior and exposure. Cigarettes with different FTC tar delivery and different taste exhibited different smoking behavior and exposure. Cigarettes with different FTC tar delivery and different taste exhibited different smoking behavior and exposure. Based on our studies taste of cigarettes seems to have no influence on smoking behavior and exposure for cigarettes with the same FTC tar delivery. Based on our studies taste of cigarettes seems to have no influence on smoking behavior and exposure for cigarettes with the same FTC tar delivery.